Amgen reported strong first-quarter results with significant revenue and earnings growth, and increased guidance for the year, reflecting confidence in their growth products and pipeline. Management's optimistic outlook and strategic initiatives outweigh concerns about specific product challenges, likely boosting investor sentiment in the short term.

[1]